Active Ingredient History
Imexon is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It is a cyanoaziridine derivative. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 1)
Burkitt Lymphoma (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Melanoma (Phase 1/Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 1)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue